Eosinophilic Esophagitis (EoE) Medication Study
What is the purpose of this study?
The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on eosinophilic esophagitis.
Who can participate?
Children, adolescents, and young adults 5 to 21 years of age, who are diagnosed with eosinophilic esophagitis, with or without a diagnosis of a connective tissue disorder including hypermobility syndrome.
What is involved?
This study lasts for approximately four months. Participation in this research study will involve 9 study visits. Of the 9 study visits, at least 3 visits will take place in the clinic or at your doctor’s office; the other visits may take place other the telephone or through the mail.
Throughout the study the following activities will occur:
- Physicals and vital signs will be obtained.
- There will be endoscopy performed at the beginning and at the end of the study.
- Blood will be obtained up to 3 times.
- Pregnancy tests will be performed.
- Quality of life questionnaires will be completed.
What are the benefits?
The information learned from this research study may benefit other patients with eosinophilic esophagitis in the future.
Will I get all the facts about the study?
Parents and adult participants will be given a consent form that thoroughly explains all the details of the study. It includes all of the procedures, the risks, the benefits, the compensation, whom to contact with questions or concerns, and more. A member of the study staff will review the consent form with you and will be sure that all of your questions are answered. Study procedures will not begin until the parent/guardian or you, have signed this form and, if of age, the child has given assent.
Do participants receive pay, compensation or reimbursement?
You will be paid a total of $185 throughout the study.
Who should I contact for more information?
The Cincinnati Center for Eosinophilic Disorders
3333 Burnet Avenue, MLC 2010
Cincinnati, OH 45229-3026
Where can I find additional information?
J. Pablo Abonia, M.D.